sorafenib has been researched along with brivanib in 13 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (brivanib) | Trials (brivanib) | Recent Studies (post-2010) (brivanib) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 86 | 19 | 71 |
| Protein | Taxonomy | sorafenib (IC50) | brivanib (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.028 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.068 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.38 | |
| Vascular endothelial growth factor receptor 2 | Mus musculus (house mouse) | 0.089 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0255 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Allen, E; Hanahan, D; Walters, IB | 1 |
| Chang, AY; Wang, M | 1 |
| Boucher, E; Chao, Y; Cheng, AL; Decaens, T; Ezzeddine, R; Han, KH; Heo, J; Hsu, CH; Hu, TH; Jeng, LB; Johnson, PJ; Komov, D; Kudo, M; Liu, D; Lu, L; Paik, SW; Park, JW; Philip, PA; Poon, RT; Qin, S; Raoul, JL; Robles-Aviña, J; Sobhonslidsuk, A; Tak, WY; Walters, I; Xu, J; Yan, L | 1 |
| Kelley, RK | 1 |
| Assenat, E; Blanc, JF; Boige, V; Boucher, E; Bruix, J; Chang, C; Chao, Y; Decaens, T; Ezzeddine, R; Fartoux, L; Finn, RS; Kang, YK; Kudo, M; Lim, HY; Lin, DY; Liu, D; Llovet, JM; Mathurin, P; Park, JW; Poon, RT; Raoul, JL; Sherman, M; Tak, WY; Walters, I | 1 |
| Hsieh, YC; Huang, YT; Lee, FY; Lee, KC; Lee, PC; Lee, WP; Lin, HC; Liu, RS; Tan, TW; Yang, YY; Yeh, YC | 1 |
| Kalyan, A; Kulik, L; Nimeiri, H | 1 |
| Costentin, C; Decaens, T; Diao, G; Duvoux, C; Katsahian, S; Laurent, A; Luciani, A; Mallat, A; Nault, JC; Nelson, AC; Pigneur, F; Tselikas, L | 1 |
| Hu, Y; Li, X; Lou, L; Tu, J; Wan, J; Wu, S; Wu, Z | 1 |
| Yang, X; Yi, C; Zhang, C; Zhu, H | 1 |
2 review(s) available for sorafenib and brivanib
| Article | Year |
|---|---|
Systemic therapy of hepatocellular carcinoma: current and promising.
Topics: Alanine; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatectomy; Humans; Indoles; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Preoperative Care; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Triazines | 2015 |
Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
Topics: Aged; Alanine; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Molecular Targeted Therapy; Randomized Controlled Trials as Topic; Risk Factors; Sorafenib; Triazines | 2018 |
2 trial(s) available for sorafenib and brivanib
| Article | Year |
|---|---|
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Double-Blind Method; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Survival Rate; Triazines; Young Adult | 2013 |
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Survival Rate; Triazines; Young Adult | 2013 |
9 other study(ies) available for sorafenib and brivanib
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
Topics: Alanine; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mice; Mice, Knockout; Mice, Transgenic; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Fibroblast Growth Factor; Sorafenib; Treatment Outcome; Triazines; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |
Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; Niacinamide; Palliative Care; Phenylurea Compounds; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Triazines | 2013 |
Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.
Topics: Alanine; Animals; Ascites; Cytokines; DNA Primers; Fatty Liver; Fibroblast Growth Factors; Microcirculation; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Platelet-Derived Growth Factor; Positron-Emission Tomography; Rats; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Splanchnic Circulation; Triazines; Vascular Endothelial Growth Factor A | 2014 |
Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors.
Topics: Aged; Alanine; alpha-Fetoproteins; Carcinoma, Hepatocellular; Female; France; Hand-Foot Syndrome; Humans; Intra-Abdominal Fat; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sarcopenia; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Triazines | 2015 |
Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report.
Topics: Alanine; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Retreatment; Sorafenib; Treatment Failure; Triazines | 2019 |